欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > Metabolism > S18-000003

浏览历史

S89184

S18-000003

源叶(MedMol) 98%
  • 英文名:
  • S18-000003
  • 别名:
  • S18-000003; S 18-000003; S-18-000003; S18000003; S 18000003; S-18000003; N-(2,4-difluorophenyl)-2-(4-(2-(4-(ethylsulfonyl)phenyl)acetamido)-2-fluorophenyl)-2-methylpropanamide
  • CAS号:
  • 2068119-11-7
  • 分子式:
  • C26H25F3N2O4S
  • 分子量:
  • 518.55
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S89184-5mg 98% ¥960.00元 5 - - - EA 加入购物车
源叶(MedMol) S89184-10mg 98% ¥1600.00元 7 - - - EA 加入购物车
源叶(MedMol) S89184-25mg 98% ¥3200.00元 6 - - - EA 加入购物车
源叶(MedMol) S89184-100mg 98% ¥8640.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述: S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC50>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations
  • 靶点: RORγt:<30 nM (IC50);ROR
  • 体外研究:
    S18-000003 inhibits human and mouse RORγt-dependent transactivation, with IC50s of 0.029 and 0.34 μM respectively in cell-based GAL4 promoter reporter assays.
    S18-000003 (0.003-0.3 μM; 7 d) dose-dependently inhibits Th17 cell differentiation from human naive CD4+T cells, with an IC50 of 0.024 μM.
    S18-000003 (0.1-3 μM; 4 d) inhibits the differentiation of mouse Th17 cells from splenic naive CD4+T cells, with an IC50 of 0.20 μM.
    S18-000003 (0.03-1 μM; 3 d) reduces the IL-17 production in human PBMCs in a dose-dependent manner, and does not inhibit either the production of other cytokines (IL-2, IL-4, IL- 10 and IFN-g) or cell proliferation.
    S18-000003 (0.1-3 μM; 3 d) reduces IL-17 and IL-22 production in PBMCs from psoriatic mice in a dose-dependent manner.
  • 体内研究:
    S18-000003 (30-100 mg/kg; po) inhibits IL-17 production in the skin of IL-23-treated mice in a dose-dependent manner.
    S18-000003 (0.1-8%; 100mL; topically administration once daily for 14 days) ameliorates psoriasis-like lesions in TPA-induced K14.Stat3C transgenic mice, and has little impact on the thymus.
    S18-000003 (0.5 mg/kg; iv) exhibits the half-life (3.2 h), AUC (1930 ng•h/mL), CLtot (4.33 mL/min/kg) and Vdss in rats.
    S18-000003 (1 mg/kg; po) exhibits the oral bioavailability (54.5%), Cmax (185 ng/mL), AUC (2110 ng•h/mL) and Tmax (4 h) in rats.
  • 参考文献:
    1: Sasaki Y, Odan M, Yamamoto S, Kida S, Ueyama A, Shimizu M, Haruna T, Watanabe A, Okuno T. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003. Bioorg Med Chem Lett. 2018 Dec 1;28(22):3549-3553. doi: 10.1016/j.bmcl.2018.09.032. Epub 2018 Sep 27. PubMed PMID: 30301676.
    [2]. Imura C, et, al. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. 2019 Mar;93(3):176-185.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 1.928 ml 9.642 ml 19.285 ml
    5 mM 0.386 ml 1.928 ml 3.857 ml
    10 mM 0.193 ml 0.964 ml 1.928 ml
    50 mM 0.039 ml 0.193 ml 0.386 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。